{"filings":[{"id":2079045,"accession_number":"0001104659-26-091099","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2026-08-05T20:11:23+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Protagonist Q2 net income $162.8M; ICOTYDE launch, rusfertide PDUFA in Aug 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2026 net income $162.8M ($2.47 basic EPS) vs net loss $34.8M in Q2 2025; revenue $213.5M from Takeda opt-out and J&J milestones.","ICOTYDE (icotrokinra) first full quarter of commercial sales; FDA approved Mar 2026; J&J partnership with up to $580M milestones and 6-10% royalties.","Rusfertide NDA under priority review for polycythemia vera; PDUFA date Aug 2026; Takeda opt-out triggered $200M payment, additional $200M and $75M upon approval.","PN-881 (oral IL-17 antagonist) Phase 2b psoriasis program planned early Q1 2027; PN-477sc (triple agonist) Phase 1 initiated.","Cash $849.5M as of June 30, 2026; potential share buyback program announcement by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1139317,"accession_number":"0001104659-26-075777","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2026-06-18T20:30:53+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Protagonist Therapeutics stockholders approve 2026 equity plan, adding 650K new shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved adoption of 2026 Equity Incentive Plan, replacing 2016 plan; adds 650,000 new shares plus carryover from prior plan and returning shares.","Dinesh Patel and Lewis Williams re-elected as Class I directors with 48.7M and 45.4M votes for, respectively.","Say-on-pay passed: 53.4M for, 3.2M against; Ernst & Young ratified as independent auditor (59.4M for, 28K against).","Plan approval received 47.7M for, 8.8M against; broker non-votes of 2.8M on all proposals except auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92509,"accession_number":"0001104659-26-055629","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protagonist Q1 net income $3.8M on ICOTYDE approval milestone; cash $620M, rusfertide opt-out fee $200M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $3.8M ($0.05 diluted EPS) vs net loss $11.7M in Q1 2025; revenue $56.4M incl. $50M ICOTYDE milestone from J&J.","Cash, equivalents & marketable securities $620.3M as of March 31, 2026; expected runway through at least 2028.","ICOTYDE FDA-approved March 18 for plaque psoriasis; Protagonist eligible for up to $580M in milestones and 6-10% tiered royalties.","Exercised rusfertide opt-out April 28, triggering $200M payment due; eligible for additional $200M opt-out fee and $75M milestone plus up to $775M sales milestones and 14-29% royalties.","Rusfertide NDA granted Priority Review; PDUFA date August 2026. PN-881 Phase 1 completion by mid-2026, Phase 2 initiation expected year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":56368000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103390,"accession_number":"0001104659-26-019658","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protagonist Q4 net loss $44.4M ($0.69/share); rusfertide opt-out expected Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net loss $44.4M ($0.69 per share) vs Q4 2024 net income $131.7M ($2.11 per share); FY2025 loss $130.1M ($2.05) vs FY2024 income $275.2M ($4.47).","License revenue fell to $7.4M in Q4 2025 from $170.6M in Q4 2024; FY2025 revenue $46.0M from $434.4M, due to lower milestones.","Cash, equivalents and marketable securities $646M as of Dec 31, 2025; provides runway through at least end of 2028.","Rusfertide NDA filed; company expects to opt out of the 50:50 profit/loss sharing with Takeda in a 90-day window opening in Q2 2026.","ICOTYDE regulatory decision anticipated in 2026 with potential launch this year; PN-881 Phase 1 completion by mid-2026; new preclinical candidates added."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":46016000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103389,"accession_number":"0001104659-26-002724","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Protagonist updates pipeline; icotrokinra NDA Jul '25, rusfertide NDA Dec '25; Phase 3 UC/CD initiated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Icotrokinra (oral IL-23R) NDA for psoriasis filed Jul '25; Phase 3 ICONIC-UC and ICONIC-CD initiated Q4 '25; superiority vs deucravacitinib achieved.","Rusfertide (hepcidin mimetic) NDA for polycythemia vera submitted Dec 29 '25; Phase 3 VERIFY met primary endpoint, p<0.0001.","PN-881 (oral IL-17) Phase 1 started Q4 '25; PN-477sc triple agonist Ph1 initiation mid-'26; PN-8047 oral hepcidin dev candidate nominated Q4 '25.","Up to $630M milestones from J&J plus 6-10% royalties; $200M opt-out payment from Takeda for rusfertide plus additional milestones.","Total potential sales milestones from icotrokinra and rusfertide up to $1.2B."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119627,"accession_number":"0001104659-25-107753","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protagonist Q3 net loss $39.3M (-$0.62); cash $678.8M; icotrokinra filed, rusfertide NDA expected Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $39.3M ($0.62 diluted EPS loss) vs $33.2M loss in Q3 2024.","Cash $678.8M, up from $559.2M at year-end 2024; provides runway through at least end 2028.","Icotrokinra NDA submitted to FDA (July) and EMA (September) for moderate-to-severe plaque psoriasis.","Rusfertide granted FDA Breakthrough Therapy designation; Phase 3 VERIFY 52-week data at ASH Dec 2025; NDA filing expected Q4 2025.","First patient dosed in Phase 1 for oral IL-17 antagonist PN-881."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":38579000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136202,"accession_number":"0001104659-25-074719","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protagonist Q2 net loss $34.8M; icotrokinra NDA filed, rusfertide NDA on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $34.8M ($0.55/share) vs $30.6M in Q2 2024; license revenue $5.5M from Takeda.","Cash $673M as of June 30, sufficient for runway through at least end 2028.","NDA for icotrokinra (moderate-to-severe plaque psoriasis) submitted to FDA in July.","Rusfertide NDA for polycythemia vera expected Q4 2025; Phase 3 VERIFY data presented at ASCO.","Pipeline: PN-477 oral/subcutaneous triple agonist for obesity selected; PN-881 IL-17 antagonist."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":33867000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153281,"accession_number":"0001104659-25-063038","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Protagonist Therapeutics shareholders elect directors, approve say-on-pay, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Harold Selick and Bryan Giraudo elected Class III directors with ~83% and ~79% of votes cast, respectively.","Non-binding advisory vote on executive compensation approved: 50.8M for, 2.9M against, 0.3M abstentions.","Ratification of Ernst & Young as independent auditor for FY 2025 approved: 55.5M for, 74k against, 0.4M abstentions.","No other proposals were submitted; broker non-votes were 1,918,517 for all director and say-on-pay items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153280,"accession_number":"0001104659-25-045073","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protagonist Q1 EPS -$0.19; rusfertide Phase 3 positive, ASCO plenary June 1","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $697.9M (up from $559.2M Dec 2024); net loss $11.7M (-$0.19/sh) vs income $207.3M in Q1 2024.","Rusfertide Phase 3 VERIFY in PV met primary endpoint (p<0.0001) and all 4 key secondaries; ASCO plenary June 1, conf call June 2.","Icotrokinra Phase 3 ICONIC-LEAD data presented at AAD and WCPD; Phase 2b ANTHEM-UC positive, full data later in 2025.","Revenue $28.3M includes $22.8M rusfertide milestone recognition; vs $255M Q1 2024 with Takeda upfront.","Pipeline: oral IL-17 antagonist PN-881 to enter clinic in 2025; cash runway through at least end of 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":28321000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172057,"accession_number":"0001104659-25-026135","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Protagonist transitions rusfertide NDA regulatory leadership to Takeda","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Takeda to lead regulatory strategy and NDA preparation for rusfertide in polycythemia vera; transition underway.","Protagonist remains primarily responsible for clinical development activities through NDA filing.","Decision made under License and Collaboration Agreement dated January 31, 2024, as amended."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172052,"accession_number":"0001104659-25-022615","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K/A","filed_at":"2025-03-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Icotrokinra shows positive Phase 2b UC (corrected p-value) and Phase 3 PsO top-line data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2b ANTHEM-UC: highest dose achieved 63.5% clinical response and 30.2% clinical remission at Wk12 vs 27.0% and 11.1% placebo; p-values corrected to <0.001 and <0.01.","Phase 3 ICONIC-LEAD: 65% IGA 0/1 and 50% PASI 90 at Wk16; at Wk24: 74% IGA 0/1, 65% PASI 90; 46% completely clear skin.","Phase 3 ICONIC-ADVANCE 1&2: met co-primary endpoints vs placebo; superior to deucravacitinib on all key secondary endpoints at Wk16 and Wk24.","Initiation of ICONIC-ASCEND: first head-to-head study of oral icotrokinra vs injectable biologic (ustekinumab) in moderate-to-severe PsO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172056,"accession_number":"0001104659-25-021986","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Icotrokinra Phase 3 PsO hits 46% complete skin clearance; UC Phase 2b meets endpoint","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 ICONIC-LEAD: 46% of icotrokinra patients achieved IGA 0 (completely clear skin) at Week 24; 74% IGA 0/1.","ICONIC-ADVANCE 1&2 met co-primary endpoints and showed superiority over deucravacitinib at Weeks 16 and 24; head-to-head vs ustekinumab (ICONIC-ASCEND) initiated.","Phase 2b ANTHEM-UC: 63.5% clinical response at highest dose at Week 12 vs 27.0% placebo (p<0.001); 30.2% clinical remission vs 11.1% (p<0.001).","Both studies show favorable safety; AEs similar to placebo. Icotrokinra is a first-in-class oral IL-23 receptor antagonist.","Results support potential paradigm shift in plaque psoriasis and ulcerative colitis; partner J&J advancing program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172055,"accession_number":"0001104659-25-019516","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Protagonist and Takeda announce positive Phase 3 topline data for rusfertide in polycythemia vera; primary endpoint met","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["77% of rusfertide patients achieved clinical response vs 33% placebo (p<0.0001) during weeks 20-32.","Mean phlebotomies per patient: 0.5 rusfertide vs 1.8 placebo (p<0.0001) over 32 weeks (EU primary endpoint).","All four key secondary endpoints met, including hematocrit control and patient-reported outcomes.","Safety profile consistent with prior studies; no new safety signals; serious AEs not drug-related.","NDA filing for rusfertide expected in second half of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172054,"accession_number":"0001104659-25-015897","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protagonist reports Q4 net income $131.7M; cash $559.2M; upcoming Phase 3 readouts in March 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $131.7M in Q4 2024 ($2.11 basic EPS) vs $27.3M in Q4 2023; FY 2024 net income $275.2M vs net loss of $79.0M in FY 2023.","License & collaboration revenue of $434.4M for FY 2024, up from $60.0M in FY 2023, including $165M milestone from JNJ.","Cash, equivalents, and marketable securities $559.2M at Dec 31, 2024; plus $165M milestone received Jan 2025; runway through at least end of 2028.","Topline results for rusfertide Phase 3 VERIFY (polycythemia vera) and icotrokinra Phase 2b ANTHEM (ulcerative colitis) expected in March 2025.","Nominated PN-881, an oral IL-17 receptor antagonist; plans to nominate oral obesity candidate in Q2 2025 and oral hepcidin candidate in Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":4.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":434433000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172053,"accession_number":"0001104659-25-001304","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Protagonist Therapeutics appoints Suneel Gupta as EVP, Clinical Development","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective Jan 1, 2025, Suneel Gupta transitioned from Chief Development Officer to EVP, Clinical Development.","Gupta, previously CDO, now serves as Executive Vice President, Clinical Development.","No other officer changes were reported in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189041,"accession_number":"0001104659-24-120165","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Protagonist announces positive Phase 3 results for icotrokinra; earns $165M milestone","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ICONIC-LEAD met co-primary endpoints: 64.7% achieved IGA 0/1, 49.6% PASI 90 at week 16 vs placebo 8.3% and 4.4%.","ICONIC-TOTAL met primary endpoint of IGA 0/1 at week 16; results in difficult-to-treat areas.","Earned $165M milestone under amended collaboration with Janssen; payment expected Q1 2025.","Company remains eligible for up to $630M in future milestones and tiered royalties of 6-10% on net sales.","Upcoming catalysts H1 2025: Phase 2b ulcerative colitis data, PsA Phase 3 start, superiority data vs deucravacitinib."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189040,"accession_number":"0001104659-24-115303","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protagonist Q3 net loss of $33.2M, cash $583M; key readouts expected in Q4 2024 and Q1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $33.2M ($0.54 per share) vs $34.1M loss in prior-year Q3.","Cash, equivalents and marketable securities $583.3M as of Sep 30, up from $341.6M at Dec 31, 2023.","License & collaboration revenue $4.7M from Takeda deal; $263.8M for nine months includes $255M upfront.","Top line results expected: JNJ-2113 Phase 3 psoriasis (ICONIC-LEAD/TOTAL) in Q4 2024; Phase 2b UC (ANTHEM) and rusfertide Phase 3 (VERIFY) in Q1 2025.","Anticipates nomination of oral IL-17 development candidate in Q4 2024; hepcidin and obesity candidates in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":2.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":263795000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205521,"accession_number":"0001104659-24-101688","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Daniel N. Swisher Jr. resigns from Protagonist board; board reduced to six","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Daniel N. Swisher Jr. resigned from the Board effective September 17, 2024; no disagreement with company operations.","Swisher will continue as an advisor to the company under an advisory agreement.","Sarah A. O'Dowd appointed to the Audit Committee effective September 19, 2024.","Board size reduced from seven to six members concurrent with Swisher's resignation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205520,"accession_number":"0001104659-24-086088","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protagonist Q2 net loss $30.6M; cash $595.4M; JNJ-2113 Phase 3 data expected Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss of $30.6M ($0.50/share) vs $38.5M loss in Q2 2023; six-month net income $176.7M from Takeda upfront.","Cash, equivalents and marketable securities of $595.4M as of June 30, 2024; runway through end of 2027.","JNJ-2113 Phase 3 ICONIC-LEAD and ICONIC-TOTAL in psoriasis primary endpoint completion expected Q4 2024.","Phase 2b ANTHEM in ulcerative colitis primary endpoint completion also expected Q4 2024; Phase 3 VERIFY rusfertide topline due Q1 2025.","Dr. Newman Yeilding appointed Chief Scientific Advisor effective August 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":2.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":259120000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222449,"accession_number":"0001104659-24-075162","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Protagonist Therapeutics shareholders approve doubling of authorized common shares to 180M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to increase authorized common shares from 90M to 180M, effective June 21, 2024.","Three Class II directors elected: Sarah O'Dowd, William Waddill, and Rusty Williams.","Advisory vote on executive compensation approved: 33.9M for, 9.3M against.","Ratification of Ernst & Young as independent auditor for FY2024 approved: 49.3M for, 115k against.","All four proposals passed; no other matters submitted at annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222448,"accession_number":"0001104659-24-058036","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protagonist Q1 net income $207.3M on $255M Takeda revenue; cash runway through Q4 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $207.3M ($3.26 diluted EPS) vs net loss of $33.7M in Q1 2023; revenue $255M from Takeda rusfertide license.","Cash, equivalents & marketable securities $322.6M at March 31, 2024; extended runway through Q4 2027 including $300M upfront from Takeda.","Phase 3 ICONIC LEAD and ICONIC TOTAL trials of JNJ-2113 in psoriasis completed enrollment; Phase 3 ICONIC ADVANCE studies ongoing.","Expect to nominate oral IL-17 antagonist development candidate by end of 2024.","Rusfertide VERIFY study top-line data expected by Q1 2025; potential deal value with Takeda up to $630M plus profit share/royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":3.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":254953000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241975,"accession_number":"0001104659-24-028208","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protagonist reports Q4 profit, $300M Takeda deal extends cash runway through 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered worldwide Takeda collaboration for rusfertide; $300M upfront, US profit share, opt-out up to $400M.","Q4 net income $27.3M ($0.45 EPS) vs loss $34.2M in Q4 2022; full year loss $79M improved from $127.4M.","Cash $341.6M; runway extended through Q4 2027 including $300M Takeda upfront.","Earned $60M in JNJ-2113 milestones from J&J in Q4; VERIFY Phase 3 enrollment on track for Q1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241974,"accession_number":"0001104659-24-008787","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2024-01-31T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Protagonist Therapeutics signs $300M upfront collaboration with Takeda for rusfertide","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Takeda pays $300M upfront within 30 days of HSR clearance; 50/50 profit-loss share in U.S.","Tiered royalties of 10-17% in ex-US territory; up to 29% if opt-out exercised.","Milestones up to $330M (no opt-out) or up to $975M (with opt-out); plus $400M opt-out payment potential.","Takeda leads global commercialization; Protagonist holds option to co-detail in U.S.","Takeda may terminate for convenience after Phase 3 data or 3rd anniversary of effective date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241973,"accession_number":"0001104659-24-003903","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2024-01-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Protagonist details rusfertide Ph3 enrollment, JNJ-2113 milestones, cash runway through Q1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rusfertide VERIFY Ph3 enrollment expected to complete 1Q24; NDA filing planned for Q4 2024.","JNJ-2113 ICONIC Ph3 program ongoing; ANTHEM UC Ph2b expected completion ~May 2025.","Oral IL-17 peptide antagonist development candidate on track for 2024.","Cash runway forecast through Q1 2026; $215M potential milestones from Janssen not included.","$172.5M in upfront and development milestones achieved, including $60M in Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241972,"accession_number":"0001104659-24-002073","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Protagonist updates pipeline: rusfertide Ph3 enrollment Q1 2024; JNJ-2113 Ph3 psoriasis data Nov 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rusfertide Phase 3 VERIFY study enrollment completion expected Q1 2024; primary endpoint similar to Phase 2.","Phase 2 REVIVE showed 69.2% responder rate vs 18.5% placebo (p=0.0003); durable Hct control to 2.5 years.","Rusfertide improved fatigue (p=0.0074) and concentration (p=0.0018) scores; ferritin normalized over 2.5 years.","JNJ-2113 Phase 3 ICONIC-LEAD psoriasis primary completion ~Nov 2024; Phase 2b ANTHEM UC completion ~Nov 2024.","Anticipated rusfertide NDA filing Q4 2026; JNJ-2113 NDA filing expected 2025/2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259388,"accession_number":"0001104659-23-113828","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protagonist Q3 net loss $34.1M; earns $50M milestone from Janssen for JNJ-2113 Phase 3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $34.1M ($0.58 per share) vs $31.2M loss in Q3 2022; R&D expenses rose to $30.7M.","Cash, equivalents and marketable securities $322.7M as of Sep 30, 2023; cash runway through Q1 2026.","JNJ-2113 Phase 3 ICONIC-LEAD, ICONIC-TOTAL trials and Phase 2b ANTHEM-UC trial initiated in Q4 2023.","Dosing of third patient in ICONIC-LEAD triggered $50M milestone from Janssen in October 2023.","Five rusfertide abstracts accepted for oral/poster presentations at ASH 2023 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259387,"accession_number":"0001104659-23-112592","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2023-10-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Protagonist Therapeutics expands board to 7, appoints Daniel Swisher as director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from 6 to 7 directors; Daniel N. Swisher, Jr. appointed as Class I director effective Oct 26, 2023.","Swisher most recently President of Jazz Pharmaceuticals (2018-2023); also serves on boards of Cerus and Corcept.","Receives $40,000 annual cash retainer and option for 45,000 shares at $14.21, vesting over 36 months.","Standard indemnification agreement entered; term runs until 2026 annual meeting.","No arrangements or family relationships with other directors or officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276658,"accession_number":"0001104659-23-087269","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protagonist Q2 net loss $38.5M; JNJ-2113 advances to Phase 3 in psoriasis","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $38.5M ($0.68/share) in Q2 2023 vs $41M loss in Q2 2022; cash $313.4M at June 30.","JNJ-2113 Phase 2b FRONTIER 1 met all endpoints; 78.6% PASI 75 at 100mg BID; moving to Phase 3 psoriasis and Phase 2b UC.","Rusfertide Phase 2 REVIVE positive results presented at EHA2023; Phase 3 VERIFY enrollment continues targeting Q1 2024 completion.","Completed $115M equity financing in April 2023.","License revenue $0 vs $0.9M in Q2 2022 as prior period included $25M milestone."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276657,"accession_number":"0001104659-23-077821","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2023-07-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Protagonist: Ph2 REVIVE hits primary endpoint (p=0.0003); Ph3 VERIFY enrollment completion expected 1Q 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2b FRONTIER 1 trial of JNJ-2113 in moderate-to-severe psoriasis completed; Phase 3 psoriasis study initiation planned.","Enrollment completion for Phase 3 VERIFY trial of rusfertide in polycythemia vera expected in 1Q 2024.","Phase 2 REVIVE study met primary endpoint with high statistical significance (p=0.0003); 69.2% responders vs 18.5% placebo.","Rusfertide showed rapid hematocrit control in PACIFIC study; safety profile generally well tolerated with no new signals.","New Phase 2b study of JNJ-2113 in ulcerative colitis planned for 4Q 2023; cash runway through end of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276656,"accession_number":"0001104659-23-077599","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2023-07-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Protagonist Therapeutics receives Nasdaq non-compliance notice for audit committee vacancy","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On June 27, 2023, Nasdaq confirmed Protagonist is not compliant with Listing Rule 5605 requiring an audit committee of at least three independent directors.","The vacancy arose after Sarah Noonberg, M.D., Ph.D. did not stand for re-election at the May 25, 2023 annual meeting.","Company has a cure period until the earlier of its next annual meeting or May 27, 2024 to fill the audit committee seat.","Board is in the process of identifying and selecting a new independent director to meet Nasdaq requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294429,"accession_number":"0001104659-23-066057","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2023-05-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Annual meeting results: Patel elected, compensation and auditor approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Dinesh V. Patel as Class I director with 32,660,198 for, 8,874,076 withheld, 3,298,693 broker non-votes.","Advisory executive compensation approved: 39,838,516 for, 1,673,050 against, 22,708 abstentions, 3,298,693 broker non-votes.","Ratified Ernst & Young as independent auditor for FY2023: 44,807,871 for, 15,794 against, 9,302 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294428,"accession_number":"0001104659-23-056018","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protagonist Q1 net loss $33.7M; positive Phase 2b data for JNJ-2113; cash runway to 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $33.7M ($0.67/share) vs $20.9M loss in Q1 2022; license revenue zero (prior year $25.7M milestone).","Positive Phase 2b FRONTIER 1 topline data for JNJ-2113 in psoriasis: PASI-75 met across all dose groups vs placebo.","Phase 2 REVIVE rusfertide data: 69.2% responders vs 18.5% placebo (p=0.0003); phlebotomy free 92.3% vs placebo.","Closed public offering of 5.75M shares at $20 each; net proceeds $108.1M; cash runway now through end of 2025.","Cash and marketable securities $230.8M; R&D expenses $27.4M (down from $36.3M); G&A $8.6M (down from $10.5M)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294427,"accession_number":"0001104659-23-043353","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2023-04-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Protagonist Therapeutics announces $100M public offering of 5M shares at $20/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["5,000,000 shares offered at $20.00 each; underwriters have 30-day option for 750,000 additional shares.","Gross proceeds expected ~$100M before underwriting discounts and expenses, closing April 10, 2023.","Underwriting syndicate led by J.P. Morgan, Jefferies, and Piper Sandler & Co.","Shares offered under effective shelf registration statement No. 333-266595."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315035,"accession_number":"0001104659-23-032774","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2023-03-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protagonist reports Q4 net loss $0.69/shr, cash $237M; positive Ph2b JNJ-2113 and rusfertide REVIVE data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss per share Q4 2022: $0.69 ($34.2M) vs $0.77 ($36.9M) in Q4 2021; full year 2022 net loss $127.4M.","Cash, cash equivalents and marketable securities $237.4M at Dec 31, 2022; expected to fund operations through end of 2024.","Phase 2b FRONTIER 1 study of JNJ-2113 in psoriasis met primary endpoint: statistically significant PASI-75 at Week 16 across all doses, well tolerated.","Phase 2 REVIVE study of rusfertide in polycythemia vera met primary endpoint: proportion of responders on rusfertide vs placebo p=0.0003; 92.3% phlebotomy-free.","License revenue from Janssen collaboration declined to zero in Q4 2022 as performance obligations completed June 2022; total milestones and royalties potential $855M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315034,"accession_number":"0001104659-23-031135","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Protagonist Therapeutics discloses limited SVB exposure, $13M at risk out of $231M total","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash at SVB approximately $13M as of March 9, 2023; company considers exposure limited.","Third-party investments of ~$218M held at multiple custodians are not directly exposed to SVB liquidity concerns.","Total cash and investments approximately $231M; company notes multiple custodians reduce risk."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315033,"accession_number":"0001104659-23-001872","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2023-01-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Protagonist Therapeutics Chief R&D Strategy Officer David Liu transitions to part-time advisor due to health reasons","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Liu stepped down as Chief R&D Strategy Officer effective Jan 1, 2023, due to health reasons.","He will continue as a part-time R&D Strategy Advisor, no longer an executive officer.","No replacement named for the role of Chief R&D Strategy Officer.","Liu is no longer a Section 16 officer, reducing executive team."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333380,"accession_number":"0001104659-22-115933","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protagonist Q3 net loss $31.2M, cash $267.4M; rusfertide Phase 3 enrollment delayed to H2 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $31.2M ($0.64 per share) vs $33.8M ($0.70) in Q3 2021; no license revenue vs $10.3M.","Cash and securities $267.4M as of Sep 30; expected to fund operations through end of 2024.","Phase 3 VERIFY enrollment completion expected H2 2023 due to site staff shortages.","Appointed Arturo Molina, M.D., M.S. as CMO, prioritizing rusfertide program.","De-prioritized PN-943; no further internal resources; seeking out-licensing."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":26581000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350876,"accession_number":"0001104659-22-086131","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protagonist Q2 net loss $41M; rusfertide Phase 3 enrollment slower, cash runway to end 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $41.0M ($0.84 per share) vs $30.8M loss in Q2 2021; license revenue $0.9M.","Cash and equivalents $291.9M, expected to fund operations through end of 2024.","Phase 3 VERIFY study enrollment slower than anticipated; target to complete enrollment by end of first half 2023.","Janssen (PN-235) advancing Phase 2b psoriasis studies; $10M milestone for second indication Phase 2 start, $50M for Phase 3 dosing.","PN-943 seeking FDA guidance for Phase 3 and partnership; IDEAL study results to be presented at UEGW Oct 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":26581000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368095,"accession_number":"0001104659-22-067589","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2022-06-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Protagonist Therapeutics stockholder meeting approves director elections, say-on-pay, and auditor ratification","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Harold Selick and Bryan Giraudo elected Class III directors with 27.9M and 28.1M votes for, respectively.","Advisory say-on-pay approved: 35.8M for, 0.4M against; 2.4M broker non-votes.","Non-binding vote favored annual say-on-pay frequency (35.6M for 1 year); company intends annual votes.","Ernst & Young ratified as auditor for FY2022: 38.7M for, 5.6K against, 1.5K abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368094,"accession_number":"0001104659-22-055918","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2022-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protagonist reports Q1 net loss $20.9M; initiates rusfertide Phase 3 VERIFY in PV","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2022 net loss $20.9M ($0.43 per share) vs $24.0M ($0.54) in Q1 2021.","License and collaboration revenue $25.7M, including $25M milestone from Janssen for PN-235.","Cash and securities $305.3M; runway through end of 2024.","Initiated Phase 3 VERIFY study of rusfertide in polycythemia vera; enrollment completion expected 1H 2023.","Phase 2 IDEAL study of PN-943 in UC met proof-of-concept at 150 mg BID; engaged PJT Partners for partnering."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":25722000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368093,"accession_number":"0001104659-22-049856","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2022-04-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"PN-943 Phase 2 IDEAL study shows 27.5% clinical remission at 150mg BID; 13% delta vs placebo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PN-943 150mg BID achieved 27.5% clinical remission vs 14.5% placebo (delta 13%, p=0.08); bio-naïve delta 16% (p=0.04).","Statistically significant histological remission (RHI≤6) at 37.2% vs 14.3% placebo (delta 23%, p=0.0107).","Endoscopic improvement: 43.1% vs 16.4% placebo (delta 26.7%, p=0.0023).","450mg BID showed no efficacy, consistent with bell-shaped dose-response observed for other α4β7 integrin antagonists.","No drug-related SAEs; safety profile similar to placebo; company plans to advance to Phase 3 registrational study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368092,"accession_number":"0001104659-22-045517","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2022-04-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA intends to rescind Breakthrough Therapy Designation for rusfertide; PN-943 Ph2 data due mid-May 2022","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA notified Protagonist of intent to rescind Breakthrough Therapy Designation for rusfertide in polycythemia vera; company requesting meeting to appeal.","PN-943 Phase 2 top-line data for ulcerative colitis expected in first half of Q2 2022 (by mid-May 2022).","Rusfertide Phase 3 VERIFY study screening underway; no anticipated changes to development plan or timelines.","Observed malignancies in rusfertide-treated patients explained; stopping rules align with background rates in PV population.","Fast Track and Orphan Drug designations for rusfertide remain active."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":387425,"accession_number":"0001104659-22-041035","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2022-03-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Protagonist Therapeutics appoints Asif Ali as EVP, CFO effective April 18, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Asif Ali, 48, appointed EVP, CFO; previously VP Finance & CAO at Theravance Biopharma (2018-2022) and VP Corp Controller at Depomed.","Annual base salary $425,000; eligible for discretionary bonus up to 40% of base salary.","Initial equity grant: option to purchase 82,500 shares (4-yr vest, 1-yr cliff) and 13,750 RSUs (4-yr equal installments).","No family relationships with any executive officer or director; no material interests in reportable transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":387424,"accession_number":"0001104659-22-037018","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2022-03-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Protagonist Therapeutics CFO Don Kalkofen resigns effective April 1, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Don Kalkofen submitted resignation effective April 1, 2022.","He will cease as principal financial and accounting officer upon resignation.","Company has initiated a search for a replacement CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":387423,"accession_number":"0001104659-22-028113","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2022-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protagonist reports Q4 2021 net loss $36.9M; cash $326.9M; rusfertide Phase 3 to start Q1 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2021 $36.9M ($0.77/share) vs $18.9M ($0.48/share) in Q4 2020; full year loss $125.6M ($2.71/share) vs $66.2M ($1.92/share).","Cash, equivalents and marketable securities $326.9M as of Dec 31, 2021; expected to fund operations through 2024.","Phase 3 VERIFY study of rusfertide in polycythemia vera to initiate Q1 2022; topline PN-943 Phase 2 UC data expected Q2 2022.","Phase 2b FRONTIER 1 study of PN-235 in plaque psoriasis initiated; $25M milestone due upon dosing third patient.","R&D expenses Q4 2021 $38.4M (vs $19.5M); full year $126.0M (vs $74.5M) on advancing pipeline and employee costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":27357000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":387422,"accession_number":"0001104659-22-025661","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2022-02-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Protagonist Therapeutics increases inducement plan share reserve by 500,000 shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Compensation Committee approved amendment to 2018 Inducement Plan on Feb 15, 2022, adding 500,000 shares (total 1,750,000).","New shares reserved exclusively for inducement grants to new employees not previously employed by the company.","Amendment adopted without stockholder approval under Nasdaq Rule 5635(c)(4) for inducement awards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":405357,"accession_number":"0001104659-21-133637","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2021-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protagonist Q3 net loss $33.8M; rusfertide hold lifted, PN-235 advancing to Phase 2","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $33.8M ($0.70/share) vs $7.8M loss in Q3 2020; revenue $10.3M (incl. $8M catch-up from Janssen amendment).","Cash $352.5M; expects to fund operations through 2024.","FDA removed clinical hold on rusfertide; Phase 3 in PV planned Q1 2022; Zealand agreement cut future milestones/royalties by 50%.","PN-943 Phase 2 IDEAL study enrollment steady; topline data from 12-week induction expected Q2 2022.","IL-23: PN-235 Phase 2 psoriasis starts early 2022; $7.5M milestone from Janssen; up to ~$900M in potential milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":18740000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":424401,"accession_number":"0001104659-21-117017","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2021-09-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA places clinical hold on Protagonist's rusfertide program after tumor finding in mouse study","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA clinical hold on all rusfertide studies after rasH2 mouse model showed benign/malignant subcutaneous skin tumors.","Four cancer cases observed across rusfertide trials assessed as unrelated; company providing additional safety data to FDA.","Dosing paused in all ongoing trials; investigators contacted to notify patients.","Rusfertide is a Phase 2 hepcidin mimetic for polycythemia vera and hereditary hemochromatosis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":424400,"accession_number":"0001104659-21-102543","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2021-08-10T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Protagonist Therapeutics resolves rusfertide dispute with Zealand Pharma, reduces royalty and milestone payments by 50%","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Royalty rate on rusfertide net sales reduced by 50% under settlement agreement.","All development and sales milestone payments for rusfertide reduced by 50%.","Company to pay $1.0M (Phase 2b milestone) and $1.5M (Phase 3 milestone) within 2 business days.","Additional $1.5M payment due in August 2022.","Future development milestones up to $2.75M; sales milestones up to $50M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":424399,"accession_number":"0001104659-21-100078","cik":1377121,"company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","form_type":"8-K","filed_at":"2021-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protagonist Q2 net loss $30.8M; rusfertide gets FDA Breakthrough Therapy; Phase 3 on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $30.8M ($0.69/share) vs $19.4M ($0.59) in Q2 2020; cash $380.4M expected to fund through 2024.","Rusfertide granted FDA Breakthrough Therapy for polycythemia vera; Phase 3 start expected early 2022.","Janssen collaboration amended: Janssen leads worldwide development; Protagonist eligible for ~$900M milestones plus $80M received.","Completed public offering of 3.5M shares at $37.75, raising ~$132.2M gross proceeds.","PN-943 Phase 2 data for ulcerative colitis anticipated in Q2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":8454000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6488374147.234517,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-08-04T23:59:59+00:00|424399"}